This MNC Pharma Stock Has A History Of Announcing Good Special Dividend; Again To Mull In July 26 Board Meet

Sanofi India has a long history of announcing good dividends and a one-time special dividend probably now year on year. So, while dividend income is always lucrative in the hands of investors as they add to your other income sources, here is everything on the stock:

Sanofi Dividend history so far

The company for the year ended 2021 announced a lucrative dividend payment of Rs. 490 per share inclusive of Rs. 309 per share special dividend. Since 2001 as per the trendlyne data, the company has announced 46 dividends of which 5 have been special dividends.

Company's financials

In the Fy21, the company's net income has doubled YoY to Rs. 944.4 crore. Also, over a period the company has managed to maintain its free cash flow. Sanofi India's standalone net profit surged 63.39% to Rs 238.40 crore on a 2.49% fall in revenue from operations to Rs 707 crore in Q1 March 2022 over Q1 March 2021.

 

 

About Sanofi India

In India, the company since 1956 offers innovative solutions in preventive healthcare (vaccines) as well as in treatment for allergy, pain, diabetes, rare diseases, and other therapeutic areas.

Should you buy the stock for good upside and lucrative dividend due to be announced soon?

Of the 7 analysts recommendation for the stock on Trendlyne, 1 give it a Hold call, 1 Strong Sell, 2 Buy and 3 Strong Buy recommendations.

Sharekhan after the quarterly results gave a buy call on the stock for a target of Rs. 9250 per share. Retaining the 'Buy' call the brokerage said diabetology shall remain its key focus and further added that "Sanofi reported strong results for Q1CY22 with operating margins expanding 139 bps y-o-y and were better than estimated, leading to a PAT ahead of estimates. Sanofi's plan to emphasize on threeareas
- accelerating growth in the diabetology space, fortifying presence in established/top brands, focusingon building brands in consumer products, could drive the growth ahead. Also expected strong growth in insulin products and portfolio expansion in cardiology could add to the growth. Emphasis on leveraging the digital platform and divestment of the slow-moving business is expected to drive OPM expansion, leading to a double- digit 10% PAT CAGR over the next two years. At the CMP, the stock trades at 26.8x/23.6x, respectively, its CY22E/CY23E estimates. High-growth visibility from chronics, strong and debt-free balance sheet, sturdy dividends, and healthy cash position are the key positives for Sanofi, hence we retain our Buy recommendation on the stock with an unchanged PT of Rs. 9,250".